Search the Newsreel

Is AbCellera Biologics Inc (ABCL) Facing Headwinds After Q2 Earnings Miss? GF Score: 59/100

AbCellera Biologics Inc (ABCL) reported a significant Q2 2026 earnings miss with revenues of $4.1 million against an estimated $7.78 million and a net loss of $55.4 million. Despite the financial shortfall, the company maintains a strong liquidity position of over $565 million in …

Abcellera Biologics earnings missed, revenue fell short of estimates

BCE in a RRIF, gold ETFs, geographic asset allocation, and more of your questions

Gordon Pape addresses readers' financial questions, discussing the suitability of BCE Inc. in an RRIF account, recommending geographic asset allocation for equity portfolios, and analyzing the CI Gold+ Giants Covered Call ETF. He also provides insights on preferred shares as an income option for …

AbCellera earnings on deck: Revenue dips as biotech eyes menopause trial

AbCellera Biologics Inc. is preparing to report its second-quarter results, with analysts forecasting a revenue decline despite recent partnership announcements. The company's cash management and the upcoming Phase 2 data readout for its lead menopause drug candidate, ABCL635, are key investor watch points. This …

Unveiling BCE (BCE) Q2 Outlook: Wall Street Estimates for Key Metrics

Wall Street analysts expect BCE (BCE) to post quarterly earnings of $0.46 per share in its upcoming report, which indicates no change from the year-ago quarter. Revenues are expected to be $4.4 billion, up 0.1% from the year-ago quarter. The consensus EPS estimate for …

AbCellera Biologics (NASDAQ:ABCL) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Spreadex Ltd Increases Stake in Beacon Energy plc (BCE) to 9.30% After Crossing Key Threshold on 31 July 2026

Abcellera Biologics Inc expected to post a loss of 14 cents a share - Earnings Preview

Abcellera Biologics Inc (ABCL) is projected to report a loss of 14 cents per share. This earnings preview is based on Refinitiv data and was published by Reuters.

Earnings Preview: BCE Inc to Report Financial Results Pre-market on August 06

BCE Inc. (NYSE:BCE) is scheduled to report its financial results before the market opens on August 6th. Analysts are projecting earnings of $0.66 per share, with revenue expected to be $4.64 billion. The company has a history of meeting or exceeding analyst consensus for …

AbCellera Biologics (ABCL) Signs Vertex Deal, Is The Stock Still Cheap?

AbCellera Biologics (ABCL) has signed a new collaboration with Vertex Pharmaceuticals for autoimmune disease treatments. Despite a recent share price rebound, the stock remains undervalued according to Simply Wall St's narrative, suggesting a fair value of $10.43 compared to its last close of $5.71. …

BCE Inc.: Katherine Lee to Resign From Board

BCE Inc. announced that Katherine Lee will resign from its Board of Directors, effective August 10, 2026. This decision was made to allow Ms. Lee to dedicate her full attention to her professional and personal commitments. She has served on the Board since April …

Rebecca McKillican joins the Board of Directors of BCE Inc.

BCE Inc. announced the appointment of Rebecca McKillican to its Board of Directors, bringing extensive experience from her leadership roles at McKesson Canada and Well.ca, as well as her current board position at National Bank of Canada. Concurrently, Katherine Lee is stepping down from …

BCE Inc. stock remains steady Friday, still outperforms market

BCE Inc. (BCE) stock remained unchanged on Friday, July 31, 2026, despite a general downturn in the Canadian market, where the S&P/TSX Composite Index fell 0.79%. The company's shares closed 16.1% below their 52-week high of C$36.25, achieved on March 17th. This indicates that …

BCE Inc (BCE) Valuation: PE, PB & Fair Value Analysis

BCE Inc's current valuation score is 8.48, placing it 24th out of 54 companies in the Telecommunications Services industry. The company's P/E ratio is 4.46, significantly below its recent high but slightly above its recent low. However, relevant data for P/B, P/S, and P/CF …

BCE INC PRF CUM REDEEMABLE 1ST SER'AE' CAD25.50 To Go Ex-Dividend On July 31st, 2026 With 0.06596 USD Dividend Per Share

BCE INC PRF CUM REDEEMABLE 1ST SER'AE' CAD25.50 (TSX:BCE-PRA.TO) is scheduled to go ex-dividend on July 31st, 2026. The company will pay a dividend of 0.06596 USD per share to shareholders. This indicates an upcoming dividend distribution for investors holding shares before the ex-dividend …

BCE Inc. Revenue Breakdown – TSX:BCE

BCE Inc. generated 24.47 billion CAD in revenue last year, with its Bell Communication and Technology Services segment contributing the most at 21.65 billion CAD. The company's revenue primarily came from Canada, accounting for 24.08 billion CAD. This financial overview highlights the key segments …

AbCellera Biologics (ABCL) Is Down 5.9% After Vertex-Backed T-Cell Engager Collaboration Announcement

AbCellera Biologics (ABCL) recently announced a collaboration with Vertex Pharmaceuticals for T-cell engagers, receiving $28 million upfront and potential milestones. This deal, along with a previous one with Jazz Pharmaceuticals, validates AbCellera's technology and provides non-dilutive cash, though the company still faces risks from …

BCE Inc. stock falls Thursday, underperforms market

BCE Inc. (BCE) shares fell 3.21% to C$30.41 on Thursday, underperforming the Canadian market as the S&P/TSX Composite Index rose 0.49%. The company's stock closed 16.1% below its 52-week high of C$36.25, achieved on March 17th. This decline occurred despite an overall positive trading …

BCE (BCE) Reports Next Week: What You Should Expect

Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when BCE (BCE) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its …

Abcellera Biologics Inc (ABCL) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Abcellera Biologics Inc (ABCL), ranking it 232 out of 384 in the Biotechnology & Medical Research industry with a financial score of 6.64. The company's financial status is weak with low operating efficiency, despite a significant year-over-year …

ABCL|Abcellera Biologics Inc|Price:5.715|Chg%:+0.025

This article provides a comprehensive stock analysis of Abcellera Biologics Inc (ABCL) based on TradingKey's proprietary scoring system. ABCL's fundamentals are described as stable with high growth potential, and its valuation is considered fair within the Biotechnology & Medical Research industry. The report highlights …

ABCL Looks 3.8% Overvalued on GF Value™

AbCellera Biologics Inc (ABCL) is indicated as 3.8% overvalued according to GuruFocus's GF Value™, though its Price-to-Sales ratio is only slightly above historical median. The company, a clinical-stage biotechnology firm, recently partnered with Vertex Pharmaceuticals, receiving a $28 million upfront payment to co-develop multispecific …

Abcellera Biologics Inc (ABCL) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Abcellera Biologics Inc (ABCL), highlighting its beta value of 1.12, indicating higher volatility compared to the S&P 500. The company's risk assessment score is 4.09, ranking it 102 out of 384 in the Biotechnology & Medical Research …

Vertex Pharmaceuticals (VRTX) Expands Its Pipeline Reach, Is The Stock Fully Valued?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Vertex Pharmaceuticals (VRTX) is back in focus after AbCellera Biologics announced a collaboration to develop multispecific T cell engagers targeting autoimmune diseases and …

AbCellera expands multispecific T-cell engager licensing with USD 28m Vertex deal for autoimmune disease

AbCellera Biologics has partnered with Vertex Pharmaceuticals in a deal worth $28 million upfront to discover and develop multispecific T-cell engagers (TCEs) for autoimmune diseases. AbCellera will lead discovery while Vertex retains development and commercialization rights, with AbCellera eligible for milestone payments and royalties. …

BCE Inc. stock rises Wednesday, outperforms market

BCE Inc. stock rose 2.05% to C$31.42 on Wednesday, outperforming the broader Canadian market which saw the S&P/TSX Composite Index fall by 1.16%. Despite the increase, BCE Inc. closed 13.3% below its 52-week high of C$36.25 reached in March. The rise occurred during a …

AbCellera partners with Vertex on autoimmune therapies

AbCellera Biologics Inc. announced a collaboration with Vertex Pharmaceuticals Incorporated to develop multispecific T-cell engagers for autoimmune diseases. AbCellera will lead discovery and early development, receiving $28 million upfront plus potential milestone payments and royalties, while Vertex funds all R&D and retains commercialization rights. …

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

VANCOUVER, British Columbia, July 29, 2026--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced a collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. "We are excited to collaborate with Vertex, a recognized …

AbCellera Biologics, Inc. Revenue Breakdown – FWB:8QQ

AbCellera Biologics, Inc. (FWB:8QQ) generated €63.97 million last year, primarily from its Antibody Medicines segment. The company's highest revenue contribution geographically came from Canada, accounting for €54.49 million. This report provides a breakdown of the company's financial performance by segment and region for the …

Healthcare of Ontario Pension Plan Trust Fund Has $13.44 Million Stake in BCE, Inc. $BCE

The Healthcare of Ontario Pension Plan Trust Fund significantly increased its stake in BCE, Inc. (NYSE:BCE) by 535.8% in the first quarter, now holding 532,508 shares valued at approximately $13.44 million. BCE's stock currently holds a consensus "Hold" rating from analysts with an average …

AbCellera Biologics (ABCL) to Post Earnings on Wednesday

Trading Systems Reacting to (BCE) Volatility

This article analyzes BCE Inc. (NYSE: BCE) for volatility, noting a neutral sentiment across all time horizons and elevated downside risk due to a lack of long-term support signals. AI-generated trading strategies are provided for position trading, momentum breakout, and risk hedging, with specific …

Stocks in play: BCE Inc.

BCE Inc. announced an enhancement to its AI-powered Suspicious Call Detection system, making it the first Canadian carrier to identify and flag spoofed calls. This new AI model detects suspicious spoofing activity beyond traditional spam, adding an extra layer of protection for customers. Following …

BCE Inc.

BCE Inc. (Bell) has announced an enhancement to its AI-powered Suspicious Call Detection system, making it the first Canadian carrier to identify and flag spoofed calls. This new AI model detects spoofing activity beyond traditional spam and fraud, adding an extra layer of protection …

BCE Inc (BCE) Cash Flow

This article provides a detailed historical cash flow statement for BCE Inc (BCE), covering quarterly and annual data for operating, investing, and financing activities. It presents key financial metrics such as operating cash flow, net income, capital expenditures, and free cash flow, along with …

BCE|BCE Inc|Price:21.255|Chg%:-0.045

This article provides a comprehensive stock analysis of BCE Inc, highlighting its stable fundamentals, high growth potential, and fair valuation within the Telecommunications Services industry. It notes a high institutional ownership, a "Hold" rating from analysts with an average price target of $36.82, and …